OC Business Journal

CANCER:

By Jessie Yount | yount@ocbj.com

EmeritusDx recently built out its cancer testing laboratory—growing from 950 square feet to 4,500 square feet—at 10 Pasteur in Irvine.

The company, formed at the beginning of 2021, made the decision to expand because it is seeing cancer testing volumes return to pre-pandemic levels, after seeing industry-wide declines as much as 40% during the pandemic, according to Chief Executive Robert Emberee.

EmeritusDx is a CLIA-certified laboratory offering anatomic pathology and fluorescence in situ hybridization services for the early detection of cancers. It is currently developing its own tests for urinary tract infections (UTI), as well as urological and gastrointestinal cancers.

It works with a variety of medical groups, surgery centers and hospitals. It also expects to generate revenue from lab services agreements with other laboratories in the future.

Emberee and President Jason Allchin launched Emeritus based on their vision of creating a laboratory with a strong employee culture that controls costs efficiently and produces the highest level of quality.

Emberee was a co-founder of Irvine-based UTI test maker Pathnostics and Allchin served there as vice president of operations. Allchin left in 2018 and Emberee departed in 2019 after the company’s sale to Water Street Healthcare Partners in 2019. Both got started in the industry at US LABS, now part of LabCorp.

The company expects to grow from about 8 to 40 employees by year’s end. Emeritus also offers a pathologist training certification program for recent college graduates.

TABLE OF CONTENTS

en-us

2021-06-21T07:00:00.0000000Z

2021-06-21T07:00:00.0000000Z

https://ocbusinessjournal.pressreader.com/article/281930250937477

LABJ